Markets
US-ECONOMY-MILKEN
PATRICK T. FALLON/Getty Images
Pensions & PE

Why is Calpers doubling down on private equity investments?

Calpers likes private equity. Is that a disaster in the making?

Jack Raines

As things stand, public pension funds are not on track to be able to fully pay pensioners when they retire. And they need to do something about it.

Since 2001, the actuarial funded ratio for state and local pensions, which measures the value of a pension’s assets against its projected benefit obligations (PBO), or the present value of future pension liabilities, has declined from 100%+ to ~78%.

In layman’s terms, public pensions don’t have enough assets to cover their expected liabilities.

So, what do you do if your pension is under-funded, such is the case with the California Public Employees’ Retirement System (Calpers)

Well, option 1 is that you could just increase your discount rate to lower the present value of future liabilities. For an incredibly simple example of how this would work, imagine that you have $80B in assets right now, your calculations show that you’ll owe $400B in 30 years, and your discount rate for these liabilities is a conservative 4.5%, which matches the 10 year treasury yield (it would make sense for pension discount rates to be conservative, but they rarely are!). The current value of those liabilities is $106.8B, and your funding ratio would be 0.75. If expected market conditions were to change in your favor (this happens all the time, actuaries just need to provide a justification), and your discount rate jumped to 5.5%, your PBO would fall to $79.8B, now matching your assets, and you’re essentially covered. Great! Nothing really changed, but the numbers look better now. This is an excellent feat of financial engineering.

(For context, most state and local pensions do use discount rates ~200+ bps higher than the risk-free rate(s) associated with the timing of their expected outflows PBO, meaning that they are probably already understating their true liabilities).

Option 2 is that you could increase your exposure to assets with higher expected returns. From Bloomberg:

The board of the California Public Employees’ Retirement System voted to boost the target allocation for private equity to 17% of its portfolio, up from 13%. It also approved increasing private credit to 8% from 5%. Based on current values, that works out to about $34 billion aimed for private equity and credit, while Calpers plans to pare its exposure to publicly traded stocks and bonds.

The shift reflects confidence that Calpers can ferret out attractive investments even as the fund significantly downgraded the expected 20-year returns from private equity in its latest market survey, citing increased financing costs. The $490 billion pension fund adopted the new asset mix following a mid-cycle review based on updated market assumptions.

For context, Calpers currently boasts a meager 72% funded ratio, and after surveying 15 institutional consultants and asset managers, they believe that private equity will outperform other asset classes, and they are investing their portfolio accordingly. 

Calpers Projections

Source: Calpers

My question is this: is private equity actually a good investment moving forward?

Bain & Company noted in their 2024 Private Equity Outlook that while global fundraising is only down 1% from its peak in 2021, global exits have fallen by 66%. Private equity investors (such as Calpers!) are investing more money than they are receiving through contributions, as there is a backlog of PE companies looking for exits.

Bain Projections
Source: Bain Capital

Source: Bain

In the absence of IPOs and acquisitions, some PE firms have turned to raising new funds, called continuation funds, to buy their own holdings, which, of course, isn’t really an exit. It’s just a firm slapping a new label on the holding company responsible for an investment, which resets the clock on management fees (typically, PE firms make more in management fees in the first 4-6 years of a fund’s life) and, more importantly, allows the firm to capture its carried interest profits from the “transaction.” This is an incredible feat of financial engineering.

So, yes, private equity has outperformed public equities over the last 20 years, but those returns aren’t 1:1 comparisons. The public market determines stock prices. If a stock is undervalued, investors typically bid the price up. If it’s overvalued, investors typically sell it down. Private markets, on the other hand, are inherently illiquid, and PE valuations are quite subjective. Firms use one of three methods: discounted cash flows (DCFs), public peer comparables, and precedent transactions, to determine values. Historically, these valuations were kept in check by exit valuations, but if you can just sell your holdings to yourself at a price you determine, well, that seems problematic. 

So Calpers, with its 72% funded ratio assuming an already aggressive discount rate of 6.8%, now wants to reallocate tens of billions of dollars to a private equity sector struggling to sell portfolio companies and distribute capital to investors. This feels like a recipe for disaster, no?

More Markets

See all Markets
markets

Nike’s China business declines for seventh straight quarter, stock sinks as soft guidance outweighs Q3 earnings beat

Sportswear kingpin Nike reported results for its third quarter, which ended in February, after the bell Tuesday. At a headline-level, the fiscal Q3 numbers were pretty solid, with Nike reporting:

  • Earnings of $0.35 per share, comfortably above the Wall Street consensus of $0.29 per share compiled by FactSet.

  • $11.28 billion in total revenue, roughly in line with the $11.26 billion estimate.

However, weakness in China and a revenue forecast that implies sales will continue to drop are weighing on the shares, which are down more than 9% in early trading on Wednesday.

On the earnings call, management said that revenue is expected to drop 2% to 4% in the coming quarter, and that overall they "expect revenues to be down low-single-digits versus the prior year, with gains in North America offset by declines in Greater China." That's a disappointment to analysts, who were anticipating 2% growth in the coming quarter, and even more in the latter stages of the year, per Bloomberg.

Nike’s sales in China — where the company earns about 15% of its revenue — fell 7% to $1.62 billion. That’s its seventh straight quarter of sales declines in the market, though this quarter’s was less than feared. The company had issued weak guidance for this quarter considering continued softness in the region.

“This quarter we took meaningful actions to improve the health and quality of our business,” said Nike CEO Elliott Hill. “The pace of progress is different across the portfolio and the areas we prioritized first continue to drive momentum.”

Nike shares are trading near decade lows this month, as tariffs continue to weigh on profits and shipping costs rise amid the war with Iran. As of Tuesday’s close, the stock was down 17% year to date.

Oil-sensitive travel stocks pop following Iran state media reporting on potential war resolution

Travel stocks are surging on Tuesday as oil prices fall following reports from Iranian state media that President Masoud Pezeshkian said the country has the necessary will to end this war, but would only do so with guarantees that prevent the recurrence of aggression.

The war has sent oil prices and refining margins surging this month, causing airlines and cruise lines to cut profit forecasts despite reported high demand.

Following Tuesday’s update, shares of the big four US airlines (Delta Air Lines, United Airlines, American Airlines, and Southwest Airlines) all climbed, along with smaller rivals including JetBlue. US airlines have stopped fuel hedging in recent years, increasing their exposure to upward swings in oil prices.

Cruise stocks also rallied, with Carnival and Norwegian up more than 6% and Royal Caribbean up about 5%.

markets

The FDA is expected to lift restrictions on certain peptides, the NYT reports

The Food and Drug Administration is expected to lift restrictions on certain peptides, allowing the experimental, often injectable substances to be sold by compounding pharmacies, The New York Times reported Tuesday.

The potential move was previously reported by The Wall Street Journal, and teased by Health Secretary Robert F. Kennedy Jr. on the “Joe Rogan Experience” podcast in late February.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

markets

Memory stocks bounce as Bernstein analyst calls TurboQuant fears “overdone”

Memory stocks rose Tuesday, after Bernstein analysts called the recent panic over Google’s TurboQuant AI algorithm “overdone.”

Bernstein analyst Mark Newman wrote:

“[Hard disk drive] and Memory stocks have sold off significantly due in part to fears from Google’s TurboQuant report. This however, should have zero impact on HDD demand and negligible impact on NAND demand. Given the stock sell-off we see this as an attractive entry point for Seagate Technology Holdings, Western Digital and Sandisk’s and upgrade WDC to Outperform.”

All three stocks were up early Tuesday, as was memory chip maker Micron.

Todays rally stands in stark contrast to the pummeling these shares have endured over the last week, after Google Research published a technical paper on March 24 detailing its TurboQuant AI algorithm, which compresses the amount of data associated with AI operations without affecting the accuracy of AI models.

That was seen as a threat to surging AI demand for memory storage, which has supercharged prices for memory chips and memory-related stocks over the last year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.